Scarica l'app Stockscreener
0.7188
2.69%
0.0188
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.70
Aprire:
$0.71
Volume 24 ore:
169.35K
Relative Volume:
0.14
Capitalizzazione di mercato:
$5.77M
Reddito:
-
Utile/perdita netta:
$-6.07M
Rapporto P/E:
-0.1244
EPS:
-5.78
Flusso di cassa netto:
$-7.34M
1 W Prestazione:
+13.38%
1M Prestazione:
+4.78%
6M Prestazione:
-29.53%
1 anno Prestazione:
-52.07%
Intervallo 1D:
$0.70
$0.74
Intervallo di 1 settimana:
$0.6106
$0.74
Portata 52W:
$0.5704
$3.00
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Nome
Adial Pharmaceuticals Inc
Settore
Industria
Telefono
434-422-9800
Indirizzo
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Confronta ADIL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.73 | 4.02M | 0 | -6.07M | -7.34M | -5.78 |
|
ONC
Beigene Ltd Adr
|
236.32 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.37 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.285 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.67 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.07 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2018-10-30 | Iniziato | Maxim Group | Buy |
| 2018-10-11 | Iniziato | Dawson James | Buy |
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
ADIL Q2 EPS Increased by Brookline Capital Management - Defense World
Adial Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharmaceuticals sets new proposal deadline - Investing.com
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stoc - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Q1 2025 Financial Results and Business Update - TradingView
Adial Pharmaceuticals Advances AUD Drug to Phase 3, Cuts Losses by 66% in Q1 2025 Earnings - Stock Titan
ADIAL PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asth - GuruFocus
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asthma Drug Development | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - The Manila Times
Adial Pharmaceuticals (ADIL) Projected to Post Quarterly Earnings on Tuesday - Defense World
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment - Investing.com Nigeria
FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04 - Psychiatric Times
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA - marketscreener.com
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program - AOL.com
Adial Pharmaceuticals (ADIL) Receives FDA Green Light for Phase 3 Meeting | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration - The Manila Times
Renaissance Technologies LLC Purchases New Stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Richmond InnoAdial Pharmaceuticals raises $2.75M - The Business Journals
Biotech Alert: Searches spiking for these stocks today - TipRanks
ADIL: Adial Pharmaceuticals Boosts Patent Portfolio with New Approval | ADIL Stock News - GuruFocus
Geode Capital Management LLC Grows Stock Holdings in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Adial Pharmaceuticals secures $2.75 million through warrant exercise By Investing.com - Investing.com Nigeria
Press Release Distribution & PR Platform - ACCESS Newswire
Adial Pharmaceuticals secures $2.75 million through warrant exercise - Investing.com
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - GlobeNewswire
Healthcare Investor Commits $2.75M to Adial Pharmaceuticals Addiction Treatment Pipeline - Stock Titan
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring - Asianet Newsable
Adial Pharmaceuticals Inc: Rising -76.71% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
How will Adial Pharmaceuticals Inc’s (ADIL) earnings compare to estimates this quarter? - uspostnews.com
Adial Pharmaceuticals (ADIL) Secures Patent for Novel Addiction Treatment Method | ADIL Stock News - GuruFocus
Adial Pharmaceuticals secures patent for addiction treatment - Investing.com Australia
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders - GlobeNewswire
Revolutionary Patent Links Genetic Markers to Personalized Addiction Treatment Success - Stock Titan
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders - Yahoo
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals CEO Weighs in on the Alcohol Pandemic and Drunk Driving Over the Holidays; FOX31 Denver's Shaul Turner Interviews Bill Stilley - ACCESS Newswire
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial - ACCESS Newswire
Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility - ACCESS Newswire
Adial Pharma stock hits 52-week low at $0.6 amid market challenges - Investing.com Australia
Adial Pharma stock hits 52-week low at $0.6 amid market challenges By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. - ACCESS Newswire
Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder - ACCESS Newswire
Adial Pharmaceuticals Inc Azioni (ADIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):